|
16 Sep 2019 |
Alnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
|
|
16 Sep 2019 |
Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3
|
|
16 Sep 2019 |
Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting
|
|
14 Sep 2019 |
Atara Biotherapeutics Reports Early Findings of Potential Efficacy from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019
|
|
12 Sep 2019 |
Adverum Biotechnologies Reports Positive 24-Week Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD
|
|
12 Sep 2019 |
Gracell Announces Interim Readout of Investigation for First-in-class FasT CAR-19 in patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and Extension in Use of FasT CAR to Other Immune Cell Programs
|
|
12 Sep 2019 |
Momotaro-Gene Announces First Patient Dosed in Phase 2 Clinical Trial of MTG201 in Combination with Nivolumab in Patients with Relapsed Malignant Pleural Mesothelioma
|
|
12 Sep 2019 |
Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944)
|
|
10 Sep 2019 |
Passage Bio Announces New Gene Therapy Development Program for Patients with Charcot-Marie-Tooth Neuropathy Type 2A
|
|
10 Sep 2019 |
Translate Bio Announces Pipeline Program Update
|
|
05 Sep 2019 |
Rocket Pharmaceuticals Announces First Patient Treated in Phase 1/2 Registrational Trial of RP-L201 for LAD-I
|
|
05 Sep 2019 |
Krystal Biotech Announces Initiation of Phase 1/2 Study of KB105 in Transglutaminase-1 (“TGM1”) Deficient Autosomal Recessive Congenital Ichthyosis (“ARCI”)
|
|
05 Sep 2019 |
Nkarta Therapeutics Raises $114 Million in Series B Financing to Advance Multiple Programs into Clinical Trials
|
|
04 Sep 2019 |
Ultragenyx Announces Positive Data from Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia
|
|
02 Sep 2019 |
The Medicines Company Presents Results from ORION-11, First Phase 3 Trial of Inclisiran, Showing Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing
|
|
29 Aug 2019 |
Immunicum AB (publ) Announces Positive Phase II MERECA Topline Results Including Complete Tumor Responses in Metastatic Renal Cell Carcinoma Patients
|
|
29 Aug 2019 |
Arrowhead Collaborator Janssen Begins REEF-1 Phase 2b Combination Study in Patients with Chronic Hepatitis B Infection
|
|
27 Aug 2019 |
The Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran
|
|
21 Aug 2019 |
NKMax America Initiates Phase I Clinical Trial of SNK in Patients with Psoriasis in Mexico
|
|
20 Aug 2019 |
Synlogic Discontinues Development of SYNB1020 to Treat Hyperammonemia
|
|
20 Aug 2019 |
Sarepta Therapeutics Receives Complete Response Letter from the US Food and Drug Administration for Golodirsen New Drug Application
|
|
16 Aug 2019 |
City of Hope Now Enrolling Patients for First-in-Human T Cell Trial for HPV-Associated Cancers
|
|
14 Aug 2019 |
NKMax America Doses First Subject in Phase I Trial of SNK in Patients with Refractory Cancer
|
|
14 Aug 2019 |
Mallinckrodt Announces Publication of Results of Phase 1b Clinical Trial of StrataGraft® Regenerative Tissue in Burns
|
|
14 Aug 2019 |
Renovacor Closes $11 Million Series A Financing to Advance First Gene Therapy for a Rare Cardiovascular Disease
|
